Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption

Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform

Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery

Expansion to SemaCyte Microcarrier platform enables optical barcoding and pooling of adherent cells to augment drug discovery high-content imaging and other screening processes Access available through Semarion’s Early Adopter Program

Camb

Semarion announces Early Adopter Programme for SemaCyte Microcarrier Platform

SemaCyte Microcarrier Platform addresses limitations within adherent cell assays to accelerate the pace of in vitro drug discovery Early access will further validate the technology and provide feedback on applicability across customer workflows

Semarion raises £2.14 million GBP ($2.89 million USD) seed funding

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced today that it has closed a £2.14 million GBP seed funding round. The investment round was led by Parkwalk Advisors, with the University of Cambridge Seed Funds, Martlet Capital, and angel investors also contributing…